Abstract
Feline infectious peritonitis (FIP) caused by feline coronavirus (FCoV) is a common dis-ease in cats, fatal if untreated, and no effective treatment is currently legally available. The aim of this study was to evaluate efficacy and toxicity of the multi-component drug Xraphconn® in vitro and as oral treatment in cats with spontaneous FIP by examining survival rate, development of clinical and laboratory parameters, viral loads, anti-FCoV antibodies, and adverse effects. Mass spectrometry and nuclear magnetic resonance identified GS-441524 as an active component of Xraphconn®. Eighteen cats with FIP were prospectively followed up while being treated orally for 84 days. Values of key parameters on each examination day were compared to values before treatment initiation using linear mixed-effect models. Xraphconn® displayed high virucidal activity in cell culture. All cats recovered with dramatic improvement of clinical and laboratory parameters and massive reduction in viral loads within the first few days of treatment without serious adverse effects. Oral treatment with Xraphconn® containing GS-441524 was highly effective for FIP without causing serious adverse effects. This drug is an excellent option for the oral treatment of FIP and should be trialed as potential effective treatment option for other severe coronavirus-associated diseases across species.
Highlights
Coronaviruses comprise a large family of RNA viruses that infect a wide variety of mammalian and avian hosts, causing severe disease in some of them [1,2,3]
The cytotoxic effect of the multi-component drug Xraphconn® solubilized in MEM or dimethyl sulfoxide (DMSO) was examined on CRFK cells using an MTT assay
Xraphconn® solubilized in MEM at 1:100 and successive log dilutions were used for the antiviral efficacy testing
Summary
Coronaviruses comprise a large family of RNA viruses that infect a wide variety of mammalian and avian hosts, causing severe disease in some of them [1,2,3]. Previous controlled treatment trials with antiviral compounds either showed limited efficacy, such as the use of feline interferon-omega [9], or were too toxic for cats, such as ribavirin [21,22,23]. In most countries, such as in Europe and the United
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
